A preliminary pharmacokinetic study of ceftazidime in premature, new born and small infants.
Fifty neonates and infants with suspected or proven bacterial infection were given 30 mg/kg of ceftazidime as a single intravenous dose to investigate the pharmacokinetics of ceftazidime. The mean serum half-lives for babies aged less than 2 months was 4.18 +/- 1.60 h and for those aged 2 to 12 months 2.00 +/- 0.64 h. Dose bands of 25 to 50 mg/kg/day for those less than two months and 50-100 mg/kg/day for those aged 2 to 12 months are recommended for the treatment of suitable bacterial infections.
D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000378:metabolism* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy*; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D007700:Kinetics
D002511:Cephalosporins; D002442:Ceftazidime